Navigation Links
Agendia BV Announces That its Chief Research Officer Laura van 't Veer has Received a 2007 Breast Cancer Research Foundation Award
Date:10/22/2007

AMSTERDAM, The Netherlands, October 22 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announced today that its Chief Research Officer Laura van 't Veer has received a prestigious 2007 Breast Cancer Research Foundation Award from the Pink Ribbon Breast Cancer Research Foundation.

The Pink Ribbon 'Breast Cancer Research Foundation' granted in New York awards to 151 international breast cancer researchers with a total value of 32 M$.

Laura van 't Veer received one of the awards together with her colleagues Martine Piccart-Gebhardt, Fatima Cardoso and Beppe Viale for their work on the European 'MINDACT' trial in which specific predictive aspects of MammaPrint(R) breast cancer prognosis assay are further tested.

Since inception in 1993 by Evelyn Lauder, the Breast Cancer Research Foundation has been solely dedicated to providing critical funding for innovative clinical and genetic research at leading medical centers worldwide.

"Laura is deeply committed to convert discoveries made in the academic setting into clinically-relevant products for the benefit of cancer patients. She co-founded Agendia exactly for that purpose. Her meticulous work enabled Agendia to become the first company to obtain clearance from the US FDA for its MammaPrint(R) breast cancer test. We are very pleased to have her and other people of her caliber in our team", said Dr. Bernhard Sixt, CEO of Agendia.

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)(x), is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation

Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

(x) CupPrint(R) is based on a license to the TUA database of AviaraDx


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... CA (PRWEB) , ... April 25, 2017 , ... ... of L3 Healthcare, is pleased to announce the company is now a certified ... The iMedNet software certification enables the company’s clinical research team to build, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Covalent ... Covalent’s Analytical Services unit provides high-quality data to clients, both faster ... hours of receipt. There are no price premiums, and customers are welcome to ...
(Date:4/24/2017)... Labs announced today the offer of whole genome sequencing (WGS) ... individuals have been able to access WGS at $1,000, this ... EUR 1,000. The sequencing includes bioinformatics analysis and ... informed decisions about disease monitoring, prevention, nutrition, exercise, health monitoring ... ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, in ... to three startups through the UConn Innovation Fund. The $1.5 million UConn Innovation ... with UConn. , The UConn Innovation Fund provides investments of up to $100,000 ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):